Generate Biomedicines Inc.
GENB | NASDAQ
$14.46
-$1.31 (-8.31%)
At close: Oct 30, 2026, 4:00 PM ET
$14.42
-$0.04 (-0.28%)
Pre-market:
Nov 2, 2026, 8:18 AM ET
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 |
|---|---|---|
Revenue | 13.54M | 7.22M |
Cost of Revenue | 3.27M | 3.27M |
Gross Profit | 10.27M | 3.95M |
Operating Income | -135.73M | -64.11M |
Interest Income | 7.54M | 2.91M |
Pretax Income | -128.89M | -61.69M |
Net Income | -128.7M | -61.45M |
Selling & General & Admin | 27.1M | 13.5M |
Research & Development | 118.89M | 54.56M |
Other Expenses | n/a | n/a |
Operating Expenses | 145.99M | 68.06M |
Interest Expense | 337K | 182K |
Selling & Marketing Expenses | n/a | n/a |
Cost & Expenses | 149.26M | 71.34M |
Income Tax Expense | 81K | 28K |
Shares Outstanding (Basic) | 128.24M | 128.19M |
Shares Outstanding (Diluted) | 128.24M | 128.19M |
EPS (Basic) | -1.06 | -0.54 |
EPS (Diluted) | -1.06 | -0.54 |
EBITDA | -124.66M | -60.84M |
EBIT | -131.16M | -64.11M |
Depreciation & Amortization | 6.5M | 3.27M |
Add to Watchlist
Select watchlists to add or remove GENB